PsiloThera is Psychedelic Healthcare Innovation

Depression is a Debilitating Global Epidemic.

Depression is the leading cause of disability in the World. Source: Psychology Today.

Globally the World Health Organization (WHO) estimates that roughly 322 Million People (4.4 percent of the World’s population) suffer from Major Depression Disorder (MDD).

The current Pandemic has had an extreme impact on those whom are already suffering. According to Psychology Today, over 16 Million American’s suffer from Clinical Depression with approximately one-third of these patients are “Treatment Resistant.”

The average number of U.S. Veteran suicides per day was 17.6 in 2018.

Globally an estimated 284 million people experienced an anxiety disorder in 2017, making it the most prevalent mental health or neurodevelopmental disorder.

Antidepressant Drugs Market is valued at USD 13.69 Billion in 2018 and expected to reach USD 15.88 Billion by 2025 with the CAGR of 2.15% over the forecast period.

Call to Action
Solving a Problem of Epic Proportions

“The Treatment of Mental Health Illness is at the forefront of a major “Paradigm Shift.”
The Global Pandemic has further exacerbated a growing population of people who suffer from mental illness.
The groundbreaking Psilocybin research could not have come at a better time. For many who have long endured & suffered…. this will be nothing short of a Miracle.”

John Atanasio, Psilothera CEO & Founder.

What We Plan to do About It

Deploy The Psilothera Online “e-Mental Health Care & Therapy Platform” & “Online Psilocybin Microdosing Dispensary Network.” Our goal of becoming the leader in e-Mental Health Care and Psilocybin Microdosing Programs.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram